| scholarly article | Q13442814 |
| P50 | author | Donna Ankerst | Q58241772 |
| P2093 | author name string | Scott A Tomlins | |
| Ian M Thompson | |||
| Ziding Feng | |||
| Robin J Leach | |||
| Martin G Sanda | |||
| John T Wei | |||
| Jonathan Gelfond | |||
| Michael A Liss | |||
| Martin Goros | |||
| Dattatraya Patil | |||
| P2860 | cites work | Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan. | Q30399140 |
| Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. | Q30664726 | ||
| Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer | Q33672510 | ||
| Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation | Q34454426 | ||
| Can urinary PCA3 supplement PSA in the early detection of prostate cancer? | Q34692263 | ||
| Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis | Q36176766 | ||
| Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. | Q36739758 | ||
| The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator | Q37001612 | ||
| Updating risk prediction tools: a case study in prostate cancer | Q37025404 | ||
| Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making | Q37241363 | ||
| Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator | Q37279076 | ||
| An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy. | Q38864086 | ||
| A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation | Q39038664 | ||
| Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial | Q39752227 | ||
| Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment | Q40281409 | ||
| Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. | Q40471358 | ||
| Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary | Q86055081 | ||
| P577 | publication date | 2018-02-05 | |
| P1433 | published in | European Urology Focus | Q27726754 |
| P1476 | title | Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator |
| Q91142766 | Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS) |
| Q64085522 | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis |
Search more.